Skip to main content
OpenTrials
Completed

NCT Number: NCT00801528

Diclofenac vs. Ropivacaine for Cesarean Section

A prospective, randomized, double blind study designed to investigate analgesic efficacy of wound infusion using diclofenac or ropivacaine following Cesarean section performed via a Pfannenstiel incision.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Meir Medical Center

Kfar Saba, 44281, Israel

About this study

Study Objective: To assess the analgesic efficacy of diclofenac or ropivacaine when administered via wound infusion.

Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Large referral hospital. Patients: 75 women recovering from Cesarean section performed via a Pfannenstiel incision.

Interventions: On completion of the surgical procedure, a 15 cm 19G infusion catheter (PAINfusor™, Baxter) will be placed below the fascia. According to a computer generated randomization schedule, patients will be divided into one of three treatment groups (n = 25).

  • In Group Control water for injection will be administered.
  • In Group Ropivacaine 0.2 % ropivacaine will be administered.
  • In Group Diclofenac diclofenac (300 mg/240 ml of water for injection) will be administered.

During the first 6 postoperative hours, a co-investigator will administer "rescue" analgesia (10 ml bolus of infusion drug or rescue morphine). Thereafter, the catheter will be connected to an elastometric pump (LV 10 Infusor, Baxter) filled with either water for injection, ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection). The fluid will be administered as a constant infusion rate (10 mL/hr). Continuous wound infusion will be continued for the subsequent 18 postoperative hours. During this 18 hour period, subcutaneous morphine 4 mg will be administered on patient request for additional analgesia.

Measurements and Main Results: The following parameters will be assessed and recorded:

  • Demographic data
  • Surgical milestones(Anesthetic time, surgical time etc).
  • Incidence of failed intrathecal anesthesia
  • VAS for pain every 15 min during first 6 postoperative hours
  • Time to first pain (intrathecal anesthesia to VAS > 60 mm)
  • Number of infusion events (10 mL and 5 mL)
  • Rescue morphine administration during first 6 postoperative hours.
  • Subcutaneous morphine administration during subsequent 18 postoperative hours.
  • VAS for pain.
  • The incidence of nausea and vomiting.
  • Patient satisfaction at 24 hours, postoperatively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing Cesarean section

Exclusion criteria

A history of clinically significant disease:

  • cardiovascular
  • pulmonary
  • hepatic
  • renal
  • neurologic
  • psychiatric
  • metabolic disease

Treatment and study plan

Ropivacaine, Diclofenac, Water for injection

Drug

Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.

Primary outcomes

  1. 1)Pain intensity 2)"Rescue" analgesia requirements

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Meir Medical Center

Other

Registry information

Official study title

The Analgesic Efficacy of Continuous Wound Instillation With Diclofenac or Ropivacaine Following Cesarean Section: a Randomized, Double-blind, Placebo Controlled Study

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Dec 3, 2008
Registry last updated
May 4, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.